One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Diagnostic Performance of Dynamic Myocardial Perfusion Imaging Using Dual-Source Computed Tomography
KakuyaKitagawaMDa?SatoshiNakamuraMDb?HidekiOtaMDcRyoOgawaMDdTakehitoShizukaMDeTadahiroKuboMDfYanYiMDgTatsuroItoMDhNaokiNagasawaRTbTakuOmoriMDiShiroNakamoriMDiTairoKuritaMDiJunSugisawaMDjNaokiHatoriMDeHitoshiNakashimaMDfYiningWangMDgTeruhitoKidoMDdKoukiWatanabeMDkYasuharuMatsumotoMDjlKaoruDohiMDiHajimeSakumaMDm
doi : 10.1016/j.jacc.2021.08.067
Volume 78, Issue 20, 16 November 2021, Pages 1937-1949
Single-center studies indicated a high diagnostic accuracy of dynamic computed tomography perfusion (CTP) imaging in the diagnosis of coronary artery disease (CAD).
Dynamic Perfusion With CT Angiography: Adding Another Feather to a Heavily Decorated Cap?
GianlucaPontoneMD, PhDaSaimaMushtaqMDaJagatNarulaMD, PhDb
doi : 10.1016/j.jacc.2021.09.016
Volume 78, Issue 20, 16 November 2021, Pages 1950-1953
Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults
Ciaran N.Kohli-LynchPhDabcBrandon K.BellowsPharmDaYiyiZhangPhDaBonnieSpringPhDdDhruv S.KaziMDeMark J.PletcherMDfEricVittinghoffPhDfNorrina B.AllenPhDdAndrew E.MoranMDa
doi : 10.1016/j.jacc.2021.08.065
Volume 78, Issue 20, 16 November 2021, Pages 1954-1964
Raised low-density lipoprotein cholesterol (LDL-C) in young adulthood (aged 18-39 years) is associated with atherosclerotic cardiovascular disease (ASCVD) later in life. Most young adults with elevated LDL-C do not currently receive lipid-lowering treatment.
Time to Relax the 40-Year Age Threshold for Pharmacologic Cholesterol Lowering?
Paul A.HeidenreichMD, MSabShoa L.ClarkeMD, PhDbDavid J.MaronMDbc
doi : 10.1016/j.jacc.2021.08.072
Volume 78, Issue 20, 16 November 2021, Pages 1965-1967
Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk
TullioPalmeriniMDaAntonio GiulioBrunoMDaBjörnRedforsMD, PhDbcdMarcoValgimigliMD, PhDeNevioTaglieriMDaFaustoFeresMDfAlexandreAbizaidMDfRicardoCostaMDfMartineGilardMDgMarie-ClaudeMoriceMDhMyeong-KiHongMD, PhDiByeong-KeukKimMD, PhDiYangsooJangMD, PhDiHyo-SooKimMD, PhDjKyung WooParkMDjAntonioColomboMDkAlaideChieffoMDlMasatoNakamuraMDmLak N.KotinkaduwaPhDbElenaNardiMStatanFrancescoSaiaMD, PhDaMauroGaspariniPhDoGiuliaRizzelloMStatoGioraWeiszMDbcAjay J.KirtaneMD, SMbcRoxanaMehranMDbpBernhardWitzenbichlerMDqNazzarenoGalièMDaGregg W.StoneMDbp
doi : 10.1016/j.jacc.2021.08.070
Volume 78, Issue 20, 16 November 2021, Pages 1968-1986
Although a 1-year duration of dual antiplatelet therapy (DAPT) is used in many patients after drug-eluting stent (DES) implantation, the evidence supporting this duration is uncertain.
Dual Antiplatelet Duration After DES: Is it Time to Say Goodbye to 1-Year DAPT??
Puja B.ParikhMD, MPH
doi : 10.1016/j.jacc.2021.08.071
Volume 78, Issue 20, 16 November 2021, Pages 1987-1989
Echocardiographic Ischemic Memory Molecular Imaging for Point-of-Care Detection of Myocardial Ischemia
Brian P.DavidsonMDaJamesHodovanRDCSaMichael E.LayounMDbHarshGolwalaMDaFirasZahrMDaJonathan R.LindnerMDab
doi : 10.1016/j.jacc.2021.08.068
Volume 78, Issue 20, 16 November 2021, Pages 1990-2000
Noninvasive molecular imaging of recent ischemia can potentially be used to diagnose acute coronary syndrome (ACS) with high accuracy.
The Potential for Retained Microbubbles: To Imaging . . . and Beyond?
Thomas R.PorterMD
doi : 10.1016/j.jacc.2021.08.069
Volume 78, Issue 20, 16 November 2021, Pages 2001-2003
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
Vishal N.RaoMD, MPHabEvanMurrayBScJavedButlerMD, MPH, MBAdLauren B.CooperMD, MHSeZachary L.CoxPharmDfMonaFiuzatPharmDbcJennifer B.GreenMDbgJoAnnLindenfeldMDhDarren K.McGuireMD, MHSciMichael E.NassifMDjCaraO’BrienMDkNehaPagidipatiMD, MPHabKavitaSharmaMDlMuthiahVaduganathanMD, MPHmOrlyVardenyPharmDnGregg C.FonarowMDoRobert J.MentzMDabStephen J.GreeneMDab
doi : 10.1016/j.jacc.2021.08.064
Volume 78, Issue 20, 16 November 2021, Pages 2004-2012
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves.
Heart Failure With Reduced Ejection Fraction: “Guideline-Directed Medical Therapy (GDMT)” Versus “The Art of Medicine”
Sheldon H.GottliebMD
doi : 10.1016/j.jacc.2021.09.015
Volume 78, Issue 20, 16 November 2021, Pages 2013-2016
Aldo R. Castañeda, MD, PhD, In Memoriam: Reflections on a Mentor and Program Leader
John E.MayerJr.MD
doi : 10.1016/j.jacc.2021.10.005
Volume 78, Issue 20, 16 November 2021, Pages 2017-2018
The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community
YasuyukiHondaMDYejinMokPhD, MPHJunichiIshigamiMD, PhD, MPHKellan E.AshleyMDRon C.HoogeveenPhDChristie M.BallantyneMDAmy B.KargerMD, PhDDavidCouperPhDElizabethSelvinPhD, MPHKunihiroMatsushitaMD, PhD
doi : 10.1016/j.jacc.2021.08.066
Volume 78, Issue 20, 16 November 2021, Pages 2019-2021
Does Repeat Revascularization Introduce Bias for Reducing Mortality in the Antiplatelet Therapy Group?
WenhuiLiMPharmHanxuZhangPhDQianXiangPhDYiminCuiMD, PhD
doi : 10.1016/j.jacc.2021.08.063
Volume 78, Issue 20, 16 November 2021, Page e171
Reply: Does Repeat Revascularization Introduce Bias for Reducing Mortality in the Antiplatelet Therapy Group?
HideyukiKawashimaMDPatrick W.SerruysMD, PhDRutaoWangMDMattiaLunardiMDYoshinobuOnumaMD, PhDSYNTAX Extended Survival Investigators
doi : 10.1016/j.jacc.2021.09.012
Volume 78, Issue 20, 16 November 2021, Pages e173-e174
